JP7012365B2 - ジカウイルスに対する新規のワクチン - Google Patents

ジカウイルスに対する新規のワクチン Download PDF

Info

Publication number
JP7012365B2
JP7012365B2 JP2018544819A JP2018544819A JP7012365B2 JP 7012365 B2 JP7012365 B2 JP 7012365B2 JP 2018544819 A JP2018544819 A JP 2018544819A JP 2018544819 A JP2018544819 A JP 2018544819A JP 7012365 B2 JP7012365 B2 JP 7012365B2
Authority
JP
Japan
Prior art keywords
zikv
prme
seq
mice
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018544819A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019506175A (ja
JP2019506175A5 (enExample
Inventor
カルッピアー ムスマニ，
デイビッド ウェイナー，
Original Assignee
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア filed Critical ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア
Publication of JP2019506175A publication Critical patent/JP2019506175A/ja
Publication of JP2019506175A5 publication Critical patent/JP2019506175A5/ja
Priority to JP2021189383A priority Critical patent/JP7555325B2/ja
Application granted granted Critical
Publication of JP7012365B2 publication Critical patent/JP7012365B2/ja
Priority to JP2024073806A priority patent/JP2024096281A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24171—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2018544819A 2016-02-25 2017-02-24 ジカウイルスに対する新規のワクチン Active JP7012365B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021189383A JP7555325B2 (ja) 2016-02-25 2021-11-22 ジカウイルスに対する新規のワクチン
JP2024073806A JP2024096281A (ja) 2016-02-25 2024-04-30 ジカウイルスに対する新規のワクチン

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201662300030P 2016-02-25 2016-02-25
US62/300,030 2016-02-25
US201662305183P 2016-03-08 2016-03-08
US62/305,183 2016-03-08
US201662396742P 2016-09-19 2016-09-19
US62/396,742 2016-09-19
US201662417100P 2016-11-03 2016-11-03
US62/417,100 2016-11-03
US201762462249P 2017-02-22 2017-02-22
US62/462,249 2017-02-22
PCT/US2017/019407 WO2017147458A1 (en) 2016-02-25 2017-02-24 Novel vaccines against zika virus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021189383A Division JP7555325B2 (ja) 2016-02-25 2021-11-22 ジカウイルスに対する新規のワクチン

Publications (3)

Publication Number Publication Date
JP2019506175A JP2019506175A (ja) 2019-03-07
JP2019506175A5 JP2019506175A5 (enExample) 2020-04-02
JP7012365B2 true JP7012365B2 (ja) 2022-03-04

Family

ID=59685658

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018544819A Active JP7012365B2 (ja) 2016-02-25 2017-02-24 ジカウイルスに対する新規のワクチン
JP2021189383A Active JP7555325B2 (ja) 2016-02-25 2021-11-22 ジカウイルスに対する新規のワクチン
JP2024073806A Pending JP2024096281A (ja) 2016-02-25 2024-04-30 ジカウイルスに対する新規のワクチン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021189383A Active JP7555325B2 (ja) 2016-02-25 2021-11-22 ジカウイルスに対する新規のワクチン
JP2024073806A Pending JP2024096281A (ja) 2016-02-25 2024-04-30 ジカウイルスに対する新規のワクチン

Country Status (10)

Country Link
US (2) US11648303B2 (enExample)
EP (1) EP3419660A4 (enExample)
JP (3) JP7012365B2 (enExample)
KR (1) KR20190003471A (enExample)
CN (2) CN115927399A (enExample)
AU (3) AU2017222644B2 (enExample)
BR (1) BR112018017307A2 (enExample)
CA (1) CA3015792A1 (enExample)
MX (2) MX2018010291A (enExample)
WO (1) WO2017147458A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA42502A (fr) 2015-07-21 2018-05-30 Modernatx Inc Vaccins contre une maladie infectieuse
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
EP3364950A4 (en) 2015-10-22 2019-10-23 ModernaTX, Inc. VACCINES AGAINST TROPICAL DISEASES
WO2017147458A1 (en) * 2016-02-25 2017-08-31 The Trustees Of The University Of Pennsylvania Novel vaccines against zika virus
CA3040123A1 (en) * 2016-10-11 2018-04-19 University Of Miami Vectors and vaccine cells for immunity against zika virus
US11806393B2 (en) * 2017-02-10 2023-11-07 La Jolla Institute For Allergy And Immunology Flavivirus peptide sequences, epitopes, and methods and uses thereof
WO2018151816A1 (en) 2017-02-16 2018-08-23 Modernatx, Inc. High potency immunogenic compositions
US10653767B2 (en) 2017-09-14 2020-05-19 Modernatx, Inc. Zika virus MRNA vaccines
CA3081586A1 (en) 2017-11-03 2019-05-09 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
CN116983398A (zh) 2017-11-30 2023-11-03 武田疫苗股份有限公司 寨卡疫苗和免疫原性组合物以及其使用方法
US11491217B2 (en) 2017-12-06 2022-11-08 Emory University Chimeric viruses encoding mutant zika virus envelope glycoproteins
BR112021001195A2 (pt) * 2018-07-23 2021-04-27 The University Of Adelaide vacina, composição farmacêutica, peptídeo imunogênico isolado, composição, métodos para elicitar uma resposta imune em um sujeito, para produzir um anticorpo antiproteína ns1 de zika, para detectar uma infecção por zica vírus e para detectar células t específicas de zika vírus, e, uso de uma vacina, uma composição farmacêutica, um peptídeo imunogênico isolado ou uma composição.
WO2020092564A1 (en) * 2018-10-31 2020-05-07 Icahn School Of Medicine At Mount Sinai Human antibodies targeting zika virus ns1, ns1 polypeptides and uses thereof
WO2020190750A1 (en) 2019-03-15 2020-09-24 Modernatx, Inc. Hiv rna vaccines
WO2022169339A1 (ko) * 2021-02-05 2022-08-11 에스티팜 주식회사 신규 핵산 분자

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012509067A (ja) 2008-11-17 2012-04-19 イノビオ ファーマシューティカルズ，インコーポレイティド フラビウイルスに対する免疫反応を引き起こす抗原及びその使用方法
WO2014144786A1 (en) 2013-03-15 2014-09-18 The Trustees Of The University Of Pennsylvania Novel vaccines against multiple subtypes of dengue virus

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU774045B2 (en) * 1998-09-02 2004-06-17 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Dengue viruses that are replication defective in mosquitos for use as vaccines
US7767210B2 (en) * 2005-12-14 2010-08-03 The Board Of Regents Of The University Of Oklahoma RNA virus vaccines and methods
CN101909635B (zh) * 2008-01-11 2014-09-17 Vgx药品有限责任公司 针对多种登革病毒亚型的新颖疫苗
CN102821790A (zh) * 2009-09-14 2012-12-12 宾夕法尼亚大学托管会 包含IL-15受体α和/或编码IL-15受体α的核酸分子的疫苗和免疫治疗剂,以及其使用方法
KR101851699B1 (ko) 2009-11-02 2018-04-24 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 구제역 바이러스(ｆｍｄｖ) 공통 단백질, 이를 위한 코딩 서열 및 이로부터 만들어진 백신
US8691961B1 (en) 2009-11-09 2014-04-08 Integral Molecular, Inc. Flavivirus reporter virus and methods of making and using the same
WO2011115583A1 (en) * 2010-03-19 2011-09-22 National University Of Singapore A novel platform for retrovirus-like particle (vlp)-display of vaccine antigens
BR112012024224A2 (pt) * 2010-03-24 2016-11-29 Arbovax Inc mutações da faixa de hospedeiro de flavivírus e seu uso.
CN105821078A (zh) * 2010-12-09 2016-08-03 巴斯德研究所 用于获得高产量重组蛋白表达的基于mgmt的方法
EA033467B1 (ru) * 2011-01-31 2019-10-31 Univ Pennsylvania Молекула нуклеиновой кислоты для индукции иммунного ответа против герпесвируса и ее применение
JP6215223B2 (ja) * 2011-12-09 2017-10-18 アンスティテュ・パストゥール マルチプレックス免疫スクリーニングアッセイ
JP6896700B2 (ja) * 2015-07-16 2021-06-30 バハラ バイオテック インターナショナル リミテッド ワクチン組成物
MA42502A (fr) 2015-07-21 2018-05-30 Modernatx Inc Vaccins contre une maladie infectieuse
EP3364950A4 (en) * 2015-10-22 2019-10-23 ModernaTX, Inc. VACCINES AGAINST TROPICAL DISEASES
US11723967B2 (en) * 2016-02-17 2023-08-15 CureVac SE Zika virus vaccine
WO2017147458A1 (en) * 2016-02-25 2017-08-31 The Trustees Of The University Of Pennsylvania Novel vaccines against zika virus
MX2019000725A (es) * 2016-07-18 2019-07-04 Variation Biotechnologies Inc Composiciones de vacuna para tratamiento de virus zika.
EP3515482A4 (en) * 2016-09-19 2020-09-30 The Wistar Institute Of Anatomy And Biology ASSOCIATION OF NEW ZIKA VIRUS VACCINES AND ANTI-DNA ANTIBODY CONSTRUCTIONS FOR USE AGAINST ZIKA VIRUS
BR112019014314A2 (pt) * 2017-01-11 2020-02-18 The Trustees Of The University Of Pennsylvania Composição, e, método de indução de uma resposta imune adaptativa contra vírus zika.
EP3412307A1 (en) * 2017-06-07 2018-12-12 Institut Pasteur Recombinant measles virus expressing zika virus proteins and their applications

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012509067A (ja) 2008-11-17 2012-04-19 イノビオ ファーマシューティカルズ，インコーポレイティド フラビウイルスに対する免疫反応を引き起こす抗原及びその使用方法
WO2014144786A1 (en) 2013-03-15 2014-09-18 The Trustees Of The University Of Pennsylvania Novel vaccines against multiple subtypes of dengue virus

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Mohammad Mahfuz，Indian J. Pharm. Biol. Res.，2014年，2(4)，44-57
Oumar Faye，PLoS Negl Trop Dis.，2014年，8(1)，1-10

Also Published As

Publication number Publication date
CN109152826B (zh) 2022-11-04
WO2017147458A1 (en) 2017-08-31
AU2017222644A1 (en) 2018-09-13
JP2022023241A (ja) 2022-02-07
AU2021258056A1 (en) 2021-11-25
JP2019506175A (ja) 2019-03-07
CN115927399A (zh) 2023-04-07
MX2018010291A (es) 2019-06-06
AU2021258056B2 (en) 2024-04-04
US20210315987A1 (en) 2021-10-14
CA3015792A1 (en) 2017-08-31
AU2024204641A1 (en) 2024-07-25
US11648303B2 (en) 2023-05-16
EP3419660A4 (en) 2019-11-06
AU2017222644B2 (en) 2021-07-29
CN109152826A (zh) 2019-01-04
JP7555325B2 (ja) 2024-09-24
US20240115689A1 (en) 2024-04-11
MX2023006203A (es) 2023-06-12
EP3419660A1 (en) 2019-01-02
BR112018017307A2 (pt) 2019-01-08
KR20190003471A (ko) 2019-01-09
JP2024096281A (ja) 2024-07-12
US12419945B2 (en) 2025-09-23

Similar Documents

Publication Publication Date Title
JP7555325B2 (ja) ジカウイルスに対する新規のワクチン
JP5744719B2 (ja) チクングニヤウィルスタンパク質の共通配列、これをコードする核酸分子、並びにこれを使用する組成物および方法
US20240226291A9 (en) Combination of novel vaccines against zika virus and dna antibody constructs for use against zika virus
KR20160091350A (ko) 중동 호흡기 증후군 코로나바이러스(MERS-CoV) 백신
KR20090046899A (ko) 개선된 백신 및 이의 사용 방법
KR101609233B1 (ko) 개량된 ｈｃｖ 백신 및 이를 이용하는 방법
KR102216962B1 (ko) 인간 파필로마 바이러스에 대한 백신 및 이것을 사용하는 방법
HK40091502A (zh) 新抗寨卡病毒疫苗
CN103889460B (zh) 改进的hcv疫苗及其使用方法
KR20170132202A (ko) Isg15 및 어쥬번트로써의 이의 용도

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181029

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200220

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210430

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210714

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211122

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211217

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220111

R150 Certificate of patent or registration of utility model

Ref document number: 7012365

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313114

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250